MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

MDT

84.21

+0.41%↑

VEEV

227.67

+3.34%↑

A

106.91

+1.84%↑

WBA

11.03

+0.46%↑

CHE

546.34

-6.7%↓

Search

Natera Inc

Slēgts

SektorsVeselības aprūpe

154.4 3.88

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

147.98

Max

154.45

Galvenie mērījumi

By Trading Economics

Ienākumi

-22M

-54M

Pārdošana

36M

476M

EPS

-0.41

Peļņas marža

-11.295

Darbinieki

4,424

EBITDA

-27M

-46M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+26.23% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 8. maijs

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-890M

20B

Iepriekšējā atvēršanas cena

150.52

Iepriekšējā slēgšanas cena

154.4

Tehniskais rādītājs

By Trading Central

Pārliecība

Bullish Evidence

Natera Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2024. g. 10. maijs 14:49 UTC

Peļņas
Karstas akcijas

Stocks to Watch Friday: TSMC, Novavax, Nvidia -- WSJ

Salīdzinājums

Cenas izmaiņa

Natera Inc Prognoze

Cenas mērķis

By TipRanks

26.23% augšup

Prognoze 12 mēnešiem

Vidējais 195 USD  26.23%

Augstākais 251 USD

Zemākais 160 USD

Pamatojoties uz 16 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Natera Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

16 ratings

16

Pirkt

0

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

147.24 / N/AAtbalsts un pretestība

Īstermiņā

Bullish Evidence

Vidējā termiņā

Bearish Evidence

Ilgtermiņā

Bullish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.